$2.23T
Total marketcap
$62.43B
Total volume
BTC 56.25%     ETH 9.03%
Dominance
us

ProPhase Labs PRPH Stock

$0.11   37.500000%
Add to favorites
Market Cap
$1.54M
LOW - HIGH [24H]
$0.08 - $0.11
VOLUME [24H]
$73.07K
P/E Ratio
0
Earnings per share
-$2.75
ISIN
US74345W1080
Price   Prediction

ProPhase Labs Price Chart

Sorry, that's all we've gotfor now...

ProPhase Labs PRPH Financial and Trading Overview

ProPhase Labs stock price 0.11 USD
Previous Close 0.08 USD
Open 0.08 USD
Bid 0.08 USD x 10942300
Ask 0.1 USD x 3000000
Day's Range 0.08 - 0.08 USD
52 Week Range 0.07 - 6.7 USD
Volume 1.61K USD
Avg. Volume 90.72K USD
Market Cap 1.12M USD
Beta (5Y Monthly) 0.069
PE Ratio (TTM) N/A
EPS (TTM) -2.75 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date May 24, 2022
1y Target Est N/A

PRPH Valuation Measures

Enterprise Value 9.59M USD
Trailing P/E N/A
Forward P/E 0.16666667
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.2580626
Price/Book (mrq) 0.14652014
Enterprise Value/Revenue 2.207
Enterprise Value/EBITDA -0.726

Trading Information

ProPhase Labs Stock Price History

Beta (5Y Monthly) 0.069
52-Week Change -97.71%
S&P500 52-Week Change 22.66%
52 Week High 6.7 USD
52 Week Low 0.07 USD
50-Day Moving Average 0.11 USD
200-Day Moving Average 1.4 USD

PRPH Share Statistics

Avg. Volume (3 month) 90.72K USD
Avg. Daily Volume (10-Days) 45.77K USD
Shares Outstanding 14.02M
Float 13.68M
Short Ratio 0.08
% Held by Insiders 2.36%
% Held by Institutions 0.071%
Shares Short 30.02K
Short % of Float 0.70%
Short % of Shares Outstanding 0.64%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:10

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) December 31, 2025
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -730.35%
Gross Margin 31.85%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -18.32%
Return on Equity (ttm) -430.66%

Income Statement

Revenue (ttm) 4.35M USD
Revenue Per Share (ttm) 0.51 USD
Quarterly Revenue Growth (yoy) -47.50%
Gross Profit (ttm) 1.38M USD
EBITDA -13215000 USD
Net Income Avi to Common (ttm) -23387000 USD
Diluted EPS (ttm) -2.75
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 90K USD
Total Cash Per Share (mrq) 0.006 USD
Total Debt (mrq) 8.62M USD
Total Debt/Equity (mrq) 245.67 USD
Current Ratio (mrq) 0.059
Book Value Per Share (mrq) 0.546

Cash Flow Statement

Operating Cash Flow (ttm) -8344000 USD
Levered Free Cash Flow (ttm) 43.01M USD

Profile of ProPhase Labs

Country United States
State NY
City Uniondale
Address 626 RXR Plaz
ZIP 11556
Phone 516 989 0763
Website https://www.prophaselabs.com
Industry Diagnostics & Research
Sector(s) Healthcare
Full Time Employees 19

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.

Q&A For ProPhase Labs Stock

What is a current PRPH stock price?

ProPhase Labs PRPH stock price today per share is 0.11 USD.

How to purchase ProPhase Labs stock?

You can buy PRPH shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for ProPhase Labs?

The stock symbol or ticker of ProPhase Labs is PRPH.

Which industry does the ProPhase Labs company belong to?

The ProPhase Labs industry is Diagnostics & Research.

How many shares does ProPhase Labs have in circulation?

The max supply of ProPhase Labs shares is 14.02M.

What is ProPhase Labs Price to Earnings Ratio (PE Ratio)?

ProPhase Labs PE Ratio is now.

What was ProPhase Labs earnings per share over the trailing 12 months (TTM)?

ProPhase Labs EPS is -2.75 USD over the trailing 12 months.

Which sector does the ProPhase Labs company belong to?

The ProPhase Labs sector is Healthcare.

ProPhase Labs PRPH included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.symbol }} {{ item.name }} {{ item.symbol }} {{ item.country.toUpperCase() }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
us US Tech Composite IXIC US 25587.04 USD
-2.21
13.85B USD 25513.26 USD 25882.57 USD 13.85B USD
us US Tech Composite Total Return XCMP US 31560.2 USD
-2.21
31469.2 USD 31924.72 USD
us US Tech Capital Market Composite RCMP US 146.53 USD
-0.75
144.14 USD 148.72 USD
Select currency